Amneal Pharmaceuticals (AMRX) Cash & Equivalents (2017 - 2026)

Amneal Pharmaceuticals' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 36.59% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 36.59% decrease from a year earlier, with the FY2025 full-year figure at $282.0 million, up 155.11% from the prior year.
• Cash & Equivalents retreated to $4.2 million in Q1 2026 per AMRX's latest filing, from $282.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $282.0 million in Q4 2025 and bottomed at $4.2 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $9.6 million (2025), against an average of $54.5 million.
• Across the five-year window, Cash & Equivalents plunged 97.77% in 2022 and soared 2284.21% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $9.3 million in 2022, then soared by 889.54% to $91.5 million in 2023, then rose by 20.77% to $110.6 million in 2024, then surged by 155.11% to $282.0 million in 2025, then tumbled by 98.52% to $4.2 million in 2026.
• Per Business Quant, the three latest AMRX Cash & Equivalents figures stand at $4.2 million (Q1 2026), $282.0 million (Q4 2025), and $34.7 million (Q3 2025).